Ameritas Advisory Services
CTXR icon

Ameritas Advisory Services’s Citius Pharmaceuticals CTXR Stock Holding History

Ameritas Advisory Services’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,000
Closed -$900 – 1987
2026
Q1 		$900 Buy
+1,000
New +$808 ﹤0.01% 1029

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Miller Financial Services
Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Asset Advisory Group
Asset Advisory Group Kinnelon, New Jersey $232M AUM 16.51% 1-Year Est. Return

Ameritas Advisory Services's CTXR Position: Q2 2026 in Review

Ameritas Advisory Services sold out of Citius Pharmaceuticals (CTXR) in Q2 2026, closing a stake of 1,000 shares — an estimated $900 sold.

Ameritas Advisory Services first reported a position in CTXR in Q1 2026 and held it in 1 quarter. The position peaked at $900 in Q1 2026. 42 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Ameritas Advisory Services reported no remaining Citius Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ameritas Advisory Services sold 1,000 Citius Pharmaceuticals shares in Q2 2026, an estimated $900.
  • Ameritas Advisory Services first reported a position in Citius Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Ameritas Advisory Services's Citius Pharmaceuticals position peaked at $900 in Q1 2026.
  • 42 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.